Recent discussions on X about Hims & Hers Health (HIMS) have been buzzing with interest following the company's dramatic stock price recovery, with a reported surge of over 40% in the past month. Many users are captivated by the telehealth firm's innovative cash-pay model and its expansion into new markets, sparking debates about its potential to reshape the healthcare landscape. The chatter reflects curiosity about whether this momentum can be sustained amidst competitive pressures.
Additionally, posts on X have highlighted mixed reactions to recent news, including FDA warnings and partnership challenges, with some expressing concern over volatility while others see these as temporary setbacks. The stock's resilience in the face of such events has kept the conversation lively, as users analyze technical indicators and speculate on future growth. This dynamic dialogue underscores the polarized views surrounding the company's trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 97 times in the past 6 months. Of those trades, 0 have been purchases and 97 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 44 sales selling 1,844,186 shares for an estimated $92,221,853.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 357,758 shares for an estimated $19,392,916.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 12 sales selling 90,501 shares for an estimated $5,358,413.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 2 sales selling 70,021 shares for an estimated $3,720,938.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 10 sales selling 100,003 shares for an estimated $3,637,319.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 13 sales selling 39,096 shares for an estimated $1,955,072.
- IRENE BECKLUND (PAO) has made 0 purchases and 4 sales selling 24,902 shares for an estimated $1,280,807.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 312 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 194 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 18,559,302 shares (+inf%) to their portfolio in Q2 2025, for an estimated $925,181,204
- D. E. SHAW & CO., INC. removed 4,143,604 shares (-68.7%) from their portfolio in Q2 2025, for an estimated $206,558,659
- INVESCO LTD. added 2,128,587 shares (+502.2%) to their portfolio in Q2 2025, for an estimated $106,110,061
- CONTRARIUS GROUP HOLDINGS LTD removed 1,749,968 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,235,904
- CLEAR STREET LLC added 1,676,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $83,581,849
- NORGES BANK added 1,574,009 shares (+inf%) to their portfolio in Q2 2025, for an estimated $78,464,348
- BANK OF MONTREAL /CAN/ added 1,515,809 shares (+5701.5%) to their portfolio in Q2 2025, for an estimated $75,563,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
- Citigroup issued a "Sell" rating on 05/06/2025
- B of A Securities issued a "Underperform" rating on 04/29/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 8 analysts offer price targets for $HIMS in the last 6 months, with a median target of $38.0.
Here are some recent targets:
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
- Korinne Wolfmeyer from Piper Sandler set a target price of $39.0 on 05/06/2025
- Daniel Grosslight from Citigroup set a target price of $30.0 on 05/06/2025
- Allen Lutz from B of A Securities set a target price of $26.0 on 04/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
